After re-examining its initial opinion, the European Medicines Agency has confirmed its recommendation to refuse marketing authorisation for the medicine Ipique. The medicine was intended for the treatment of neovascular (wet) age-related macular degeneration (AMD).
The Agency issued its opinion after re-examination on 24 February 2022. The Agency had issued its initial opinion on 11 November 2021. The company that applied for authorisation of Ipique is Rotterdam Biologics B.V.
Questions and answers on the refusal of the marketing authorisation for Ipique (bevacizumab) (PDF/100 KB)
First published: 12/11/2022
Last updated: 24/05/2022
|International non-proprietary name (INN) or common name||
|Therapeutic area (MeSH)||
Wet Macular Degeneration
|Anatomical therapeutic chemical (ATC) code||
Rotterdam Biologics B.V.
|Date of opinion||
|Date of refusal of marketing authorisation||
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 21-24 February 202225/02/2022
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24-27 January 202228/01/2022
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 8-11 November 202112/11/2021